ESSA Pharma Inc. (EPIX): Price and Financial Metrics
EPIX Price/Volume Stats
| Current price | $5.30 | 52-week high | $6.40 |
| Prev. close | $5.36 | 52-week low | $2.29 |
| Day low | $5.16 | Volume | 42,900 |
| Day high | $5.61 | Avg. volume | 128,727 |
| 50-day MA | $4.37 | Dividend yield | N/A |
| 200-day MA | $3.29 | Market Cap | 233.74M |
EPIX Stock Price Chart Interactive Chart >
ESSA Pharma Inc. (EPIX) Company Bio
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is based in Vancouver, Canada.
Latest EPIX News From Around the Web
Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.
Director Franklin Berger Bolsters Position in ESSA Pharma Inc with Purchase of 23,259 SharesRecent insider trading activity has caught the attention of market analysts and investors alike, as Director Franklin Berger executed a significant purchase of shares in ESSA Pharma Inc (NASDAQ:EPIX). |
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 12:00 p.m. ET in New York. |
ESSA Pharma to Present at the Jefferies London Healthcare ConferenceESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m. ET in London. |
ESSA Pharma Enters into At-The-Market Equity Offering Sales AgreementESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of November 3, 2023. Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$50.0 million in aggregate sales proceeds. No |
We Think ESSA Pharma (NASDAQ:EPIX) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
EPIX Price Returns
| 1-mo | -11.67% |
| 3-mo | 85.31% |
| 6-mo | 67.19% |
| 1-year | 52.74% |
| 3-year | -21.25% |
| 5-year | 100.76% |
| YTD | 110.32% |
| 2022 | -82.25% |
| 2021 | 19.03% |
| 2020 | 116.91% |
| 2019 | 161.90% |
| 2018 | -52.05% |
Loading social stream, please wait...